MARC details
| 000 -LEADER |
|---|
| fixed length control field |
05134cam a2200361 i 4500 |
| 001 - CONTROL NUMBER |
|---|
| control field |
373480760 |
| 005 - DATE AND TIME OF LATEST TRANSACTION |
|---|
| control field |
20201112121525.0 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
|---|
| fixed length control field |
081201s2010 paua b 001 0 eng |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER |
|---|
| International Standard Book Number |
9780702029837 (hbk.) |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER |
|---|
| International Standard Book Number |
0702029831 (hbk.) |
| 040 ## - CATALOGING SOURCE |
|---|
| Original cataloging agency |
UKM |
| Transcribing agency |
UKM |
| Modifying agency |
C#P |
| -- |
YDXCP |
| -- |
OS2 |
| -- |
UtOrBLW |
| Description conventions |
rda |
| 050 #4 - LIBRARY OF CONGRESS CALL NUMBER |
|---|
| Classification number |
RE46 |
| Item number |
.O28 2010 |
| 082 04 - DEWEY DECIMAL CLASSIFICATION NUMBER |
|---|
| Classification number |
617.7 |
| Edition number |
22 |
| Item number |
O |
| 245 00 - TITLE STATEMENT |
|---|
| Title |
Ocular disease : |
| Remainder of title |
mechanisms and management / |
| Statement of responsibility, etc |
[edited by] Leonard A. Levin, Daniel M. Albert. |
| 264 #1 - PUBLICATION, DISTRIBUTION, ETC. (IMPRINT) |
|---|
| Place of publication, distribution, etc |
[Philadelphia] : |
| Name of publisher, distributor, etc |
SaundersElsevier, |
| Date of publication, distribution, etc |
[2010] |
| 264 #4 - PUBLICATION, DISTRIBUTION, ETC. (IMPRINT) |
|---|
| Date of publication, distribution, etc |
©2010 |
| 300 ## - PHYSICAL DESCRIPTION |
|---|
| Extent |
xv, 687 pages : |
| Other physical details |
illustrations (some color) ; |
| Dimensions |
29 cm |
| 336 ## - CONTENT TYPE |
|---|
| Source |
rdacontent |
| Content type term |
text |
| 337 ## - MEDIA TYPE |
|---|
| Source |
rdamedia |
| Media type term |
unmediated |
| 338 ## - CARRIER TYPE |
|---|
| Source |
rdacarrier |
| Carrier type term |
volume |
| 500 ## - GENERAL NOTE |
|---|
| General note |
"Expert consult"--Cover. |
| 504 ## - BIBLIOGRAPHY, ETC. NOTE |
|---|
| Bibliography, etc |
Includes bibliographical references and index. |
| 505 0# - FORMATTED CONTENTS NOTE |
|---|
| Formatted contents note |
SECTION 1 Cornea -- <br/>1. Loss of corneal transparency -- <br/><br/>2. Abnormalities of corneal wound healing -- <br/><br/>3. Wound healing after laser in situ keratomileusis and photorefractive keratectomy -- <br/><br/><br/>4. Genetics and mechanisms of hereditary corneal dystrophies -- <br/><br/><br/>5. Fuchs’ endothelial corneal dystrophy -- <br/><br/><br/>6. Keratoconus -- <br/><br/><br/>7. Infectious keratitis -- <br/><br/><br/>8. Corneal graft rejection -- <br/><br/><br/>9. Corneal edema -- <br/><br/><br/>10. Corneal angiogenesis and lymphangiogenesis -- <br/><br/><br/>11. Ocular surface restoration -- <br/><br/><br/>12. Herpetic keratitis -- <br/><br/><br/>13. Ocular allergy -- <br/><br/>SECTION 2 Dry eye -- <br/><br/>14. The lacrimal gland and dry-eye disease -- <br/><br/><br/>15. Immune mechanisms of dry-eye disease -- <br/><br/>16. Disruption of tear ?lm and blink dynamics -- <br/><br/><br/>17. Abnormalities of eyelid and tear ?lm lipid -- <br/><br/>18 Dry eye: abnormalities of tear ?lm mucins -- <br/><br/>SECTION 3 Glaucoma -- <br/><br/>19. Steroid-induced glaucoma -- <br/><br/>20. Biomechanical changes of the optic disc -- <br/><br/><br/>21. Pigmentary dispersion syndrome and glaucoma -- <br/><br/>22. Abnormal trabecular meshwork out?ow -- <br/><br/>23. Pressure-induced optic nerve damage -- <br/><br/>24. Exfoliation (pseudoexfoliation) syndrome -- <br/><br/>25. Angle closure glaucoma -- <br/><br/>26. Central nervous system changes in glaucoma -- <br/><br/>27. Retinal ganglion cell death in glaucoma -- <br/><br/>28. Wound-healing responses to glaucoma surgery -- <br/><br/>29. Blood ?owchanges in glaucoma -- <br/><br/>Leopold Schmetterer and Mark Lesk -- <br/><br/>SECTION 4 Lens -- <br/><br/>30. Biochemical mechanisms of age-related cataract -- <br/><br/>31. Posterior capsule opaci?cation -- <br/><br/>32. Diabetes-associated cataracts -- <br/><br/>33. Steroid-induced cataract -- <br/><br/>34. Presbyopia -- <br/><br/>35. Restoration of accommodation -- <br/><br/><br/>36. Intraoperative ?oppy iris syndrome -- <br/> <br/><br/>SECTION 5 Neuro-ophthalmology -- <br/><br/>37. Optic neuritis -- <br/><br/><br/>38. Abnormal ocular motor control -- <br/><br/><br/>39. Idiopathic intracranial hypertension (idiopathic pseudotumor cerebri) -- <br/><br/><br/>40. Giant cell arteritis -- <br/><br/><br/>41. Ischemic optic neuropathy -- <br/><br/>42. Optic nerve axonal injury -- <br/><br/>43. Leber’s hereditary optic neuropathy -- <br/><br/>44. Optic atrophy -- <br/><br/>45. Nystagmus -- <br/><br/>46. Toxic optic nerve neuropathies -- <br/> <br/> <br/>SECTION 6 Oncology -- <br/><br/>47. Uveal melanoma --<br/><br/><br/>48. Genetics of hereditary retinoblastoma -- <br/><br/><br/>49. Molecular basis of low-penetrance retinoblastoma -- <br/><br/><br/>50. Vasculogenic mimicry -- <br/><br/><br/>51. Treatment of choroidal melanoma -- <br/><br/><br/>52. Sebaceous cell carcinoma -- <br/><br/> <br/>53. Neuro?bromatosis --<br/><br/><br/> <br/><br/>SECTION 7 Other<br/><br/>54 Phthisis bulbi --<br/><br/>55. Myopia --<br/><br/><br/>56. Pathogenesis of Graves’ ophthalmopathy -- <br/><br/> <br/> <br/><br/>SECTION 8 Pediatrics -- <br/><br/>57. Duane syndrome --<br/><br/><br/>58. Amblyopia --<br/><br/><br/>59 Strabismus --<br/><br/><br/>60. Albinism --<br/><br/><br/>61. Aniridia --<br/><br/><br/> <br/><br/>SECTION 9 Retina --<br/><br/>62. Color vision defects --<br/><br/><br/>63. Acute retinal vascular occlusive disorders --<br/><br/><br/>64. Retinal photic injury: laboratory and clinical ?ndings --<br/><br/><br/>65. Vascular damage in diabetic retinopathy --<br/><br/><br/>66. Neovascularization in diabetic retinopathy --<br/><br/><br/>67. Diabetic macular edema --<br/><br/><br/>68. Dry age-related macular degeneration and age-related macular degeneration pathogenesis --<br/><br/><br/>69. Neovascular age-related macular degeneration --<br/><br/>70. Inhibition of --<br/><br/><br/>71. Retinal detachment --<br/><br/><br/>72. Retinopathy of prematurity --<br/><br/><br/>73. Retinal energy metabolism --<br/><br/><br/>74. Retinitis pigmentosa and related disorders --<br/><br/><br/>75 Visual prostheses and other assistive devices --<br/><br/><br/>76. Paraneoplastic retinal degeneration --<br/><br/><br/>77. Cellular repopulation of the retina --<br/><br/><br/>78. Proliferative vitreoretinopathy --<br/><br/><br/> <br/><br/>SECTION 10 Uveitis --<br/><br/>79. Immunologic mechanisms of uveitis --<br/><br/><br/>80. Herpesvirus retinitis --<br/><br/><br/>81. Sympathetic ophthalmia -- <br/><br/><br/>82. Scleritis -- <br/><br/><br/>83 Infectious uveitis --<br/><br/><br/>84. Ocular sarcoidosis --<br/><br/><br/><br/> <br/><br/>Index |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name as entry element |
Ophthalmology. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name as entry element |
Eye |
| General subdivision |
Diseases. |
| 9 (RLIN) |
33218 |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name as entry element |
Eye |
| General subdivision |
Diseases |
| -- |
Treatment. |
| 9 (RLIN) |
33219 |
| 700 1# - ADDED ENTRY--PERSONAL NAME |
|---|
| Personal name |
Levin, Leonard A. |
| 9 (RLIN) |
33220 |
| Relator term |
editor. |
| 700 1# - ADDED ENTRY--PERSONAL NAME |
|---|
| Personal name |
Albert, Daniel M. |
| 9 (RLIN) |
33221 |
| Relator term |
editor. |
| 856 ## - ELECTRONIC LOCATION AND ACCESS |
|---|
| Materials specified |
Abstract |
| Uniform Resource Identifier |
<a href="http://repository.fue.edu.eg/xmlui/handle/123456789/1651">http://repository.fue.edu.eg/xmlui/handle/123456789/1651</a> |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) |
|---|
| Koha item type |
Books |
| Source of classification or shelving scheme |
Dewey Decimal Classification |